Currently Viewing:
Patient-Centered Oncology Care
Dr Mark Fleury Highlights ACS CAN's Advocacy Efforts
June 11, 2018
Dr Mark Fleury Highlights ACS CAN's Involvement in the FDA's Patient-Focused Drug Development Initiative
June 02, 2018
Ian Manners Outlines Pharma's Participation in Providing Financial Assistance for Patients
May 23, 2018
Dr Mark Fleury on 21st Century Cures and Cancer Care
May 21, 2018
Ian Manners Explains How Vivor Empowers Providers and Financial Navigators
May 03, 2018
Dr Thomas Graf: Personalizing Cancer Care Payment Models
April 16, 2018
Dr Stacey McCullough Discusses Teamwork and Collaboration in Oncology
April 13, 2018
Torrie Fields: Collecting and Using Data Can Better Inform a Patient
April 12, 2018
Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage
April 06, 2018
Kathleen Lokay: Incorporating the Latest Research and Supporting Physicians
April 05, 2018
Dr Stacey McCullough on the Pharmacist's Role in Patient Education
March 29, 2018
Dr Thomas Graf: How the Impact of Novel Therapies Varies Among Stakeholders
March 22, 2018
Jason Harris Highlights National Health Council's Recommendations on Real-World Evidence
March 18, 2018
Ian Manners Explains the Impact of Patient Financial Assistance Programs
March 17, 2018
Dr Thomas Graf on the Impact of New Therapies in Oncology
March 12, 2018
Jason Harris: Improving Patient Understanding and Promoting High-Value Care
March 02, 2018
Dr Brenton Fargnoli on Fixing Issues Physicians Have With EHRs
February 18, 2018
Currently Reading
Kathleen Lokay: Implementing Value in Clinical Pathways
February 13, 2018
Dr Brenton Fargnoli Explains How Quality Measurement Benchmarks Drive Action
February 09, 2018

Kathleen Lokay: Implementing Value in Clinical Pathways

Via Oncology is taking several steps to implement value into clinical pathways programs, explained President and CEO Kathleen Lokay.


Via Oncology is taking several steps to implement value into clinical pathways programs, explained President and CEO Kathleen Lokay.

Transcript

How is Via Oncology working to implement value into clinical pathway programs?

It’s really at several levels. One is that we’ve always taken the approach that we want the committees if everything else is really comparable in terms of efficacy and toxicity, we want the committees to drive to the approach that is the least costly to the patient and the payer. So we’ve always incorporated value at that third test. What we’re also hearing from our customers is that they want more information to be able to have shared discussions with patients when maybe the thing that has better efficacy maybe has a price tag that is just too high for that patient. So we’ve developed a cost analyzer tool to let the physicians have access to the information in those shared decision-making situations.

And then the third thing is our committees are increasingly carving out patient presentations for not clinical presentations, but financial presentations so we may have a pathway branch for a patient who can’t afford the copay on an oral drug and will instead provide an IV alternative that has a lower copay or no copay so the committees have the ability to really create those more value based scenarios based on patient preference.

What we’re not doing, and I don’t know when we will, is we’re not asking the committees to decide whether three extra months of survival is worth a certain price tag. We don’t feel that there is a societal agreement on what that is today so we certainly don’t want to be asking our committees to be making that judgement call.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!